loader2
Partner With Us NRI

Metropolis Healthcare Ltd share Price Today

Company details

1,931.00
1,973.15
1,296.00
2,067.95
6M Return 19.48%
1Y Return 40.76%
Mkt Cap.(Cr) 9,910.89
Volume 26,052
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 26,052

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Healthcare Services company Metropolis Healthcare announced Q4FY24 & FY24 results:

  • Core Business Revenue increased by 15% for Q4FY24 & 13% for FY24 on YoY basis
  • Core Business patient volume stood at 2.98 million for Q4FY24 and 11.59 million for FY24 with a growth of 7% & 9% respectively on YoY basis
  • B2C Revenue grew by 20% for Q4FY24 YoY
  • TruHealth Wellness & Specialized segment revenues grew by 22% & 17% respectively for Q4FY24 on YoY basis
  • Reported EBITDA stood at 25.5% for Q4FY24. EBITDA before CSR & ESOP stood at 26.4%.
  • Contribution of premium wellness stood at 15% in Q4FY24.
  • B2C revenue growth in Mumbai at 20% in Q4FY24 YoY.

Ameera Shah, Managing Director, Metropolis Healthcare, said, “We have consistently surpassed industry volume growth for the past eight quarters and remain optimistic about continuing this trend. Despite significant network expansion over the last two years, we achieved EBITDA margins of 25.5% in Q4 FY24. Looking ahead, we expect additional revenue from both existing and new networks, coupled with improved operational efficiency, to sustain our current margin levels in FY25 and further enhance our margin profile beyond FY25.

Over the past many years, we have been focusing on professionalizing the company and have been adding talent to our senior management team. With Surendran & the team of CXO’s, in place and delivering results, I am more confident of achieving greater heights. We believe this is an appropriate time for me to hand over the baton to Surendran & team to execute our strategies, while I will move to the position of Executive Chairperson & Whole Time Director with steady focus on driving the strategy, strengthening governance, strategizing capital allocation, acquiring talent and foster the culture at Metropolis.

As we progress with our Metropolis 3.0 strategy, along with organic growth via existing network and expansion. M&A will be pivotal in elevating our position. Our goal is to enhance our technical testing capabilities and enter new markets, bolstering our strengths and ensuring sustainable growth.”

Surendran Chemmenkotil, CEO, Metropolis Healthcare, said, "As we reflect on our Q4 performance, I am delighted to share our remarkable achievements, in Q4FY24, our core business revenues grew by 15% year-on-year, with volume growth of 7% . Our B2C revenues grew by ~20% y-o-y, additionally, our revenues from Mumbai market witnessed an impressive growth of 20%, highlighting our brand strength. Looking ahead, we are confident in scaling up revenue in the coming quarters, showcasing a promising trend of positive operating leverage.

Guided by our strategic vision, we have diligently focused on expanding our network, driving volume and revenue growth, and optimizing efficiency, productivity, and margins. We have expanded our footprint significantly, from around 300 towns in FY23 to surpassing 600 towns by FY24, with intentions to extend our coverage nationwide. We are reinforcing our strategy of expanding our footprints venturing into Tier 3 and Tier 4 towns, while also concentrating efforts in vital clusters across our core geographies

Going forward with brand strength of metropolis, talent pool, trusted partners for doctors and consumers coupled with aggressive expansion plans, foray into adjacencies with opportunities of inorganic growth, we are optimistic of outnumbering in the industry growth in terms of revenue growth and profitability."

Result PDF

View Other Company Results

Metropolis Healthcare Ltd shares SWOT Analysis

Resistance and support

R1 1,979.4
R2 2,003.6
R3 2,032.3
Pivot

1,950.75

S1 1,926.6
S2 1,897.9
S3 1,873.7
EMA SMA
1,945.0
1,870.6
1,787.8
1,689.2
1,961.6
1,858.4
1,760.8
1,652.6
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2023-12-21 1690.38 259625 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Sell 2023-12-21 1683.49 280825 NSE
GRANDEUR PEAK GLOBAL TRUST GRANDEUR PEAK INTERNATIONAL STALWARTS FUND Bulk Purchase 2023-10-20 1509.95 399485 BSE
Name Category Shares
Sushil Kanubhai Shah PROMOTER 2.5%
Metz Advisory Llp PROMOTER 30.63%
Duru Shah Family Trust PROMOTER 9.69%
Sushil Shah Family Trust PROMOTER 4.99%
Duru Sushil Shah PROMOTER 1.49%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Metropolis Healthcare Ltd Stocks COMPARISON

Financials( in Cr) Metropolis Healthcare Ltd Apollo Hospitals Enterprise Ltd Max Healthcare Institute Ltd Fortis Healthcare Ltd Global Health Ltd
Price 1,934.70 6,138.05 895.85 489.95 1,353.25
% Change -1.05 -1.58 -0.80 -0.72 -1.47
Mcap Cr 9,910.89 88,255.95 87,068.74 36,989.17 36,335.71
Revenue TTM Cr 1,148.21 16,612.50 4,831.37 6,537.06 2,694.25
Net Profit TTM Cr 143.39 887.50 1,103.51 632.98 326.08
PE TTM 78.33 99.87 82.94 63.47 77.03
1 Year Return 40.76 19.30 48.90 59.67 112.01
ROCE 17.23 14.16 13.85 7.51 16.49
ROE 15.30 15.04 16.12 6.79 16.13
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 988.23 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 32,550.52 645.34
LAST 3M 103,712.87 -29,605.88
LAST 6M 176,931.00 -14,371.69
LAST 12M 290,309.13 100,312.35

Metropolis Healthcare Ltd Information

Stock PE (TTM)
78.33
Promoter Holding
49.67%
Book Value
213.9725
ROCE
17.23%
ROE
15.3%
Registered Address

250 D Udyog Bhavan, Worli, Mumbai, Maharashtra, 400030

Tel : 91-22-62582810
Email : investor.relations:metropolisindia.com
Website : http://www.metropolisindia.com
Registrar

Link Intime India Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 542650
NSE Code : METROPOLIS
Book Closure Date (Month) : Aug
BSE Group : A
ISIN : INE112L01020

FAQ’s on Metropolis Healthcare Ltd Shares

You can buy Metropolis Healthcare Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Metropolis Healthcare Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 19, 2024 10:29 AM the closing price of Metropolis Healthcare Ltd was Rs.1,934.70.

The latest PE ratio of Metropolis Healthcare Ltd as of Jun 19, 2024 10:29 AM is 78.33

The latest PB ratio of Metropolis Healthcare Ltd as of Jun 19, 2024 10:29 AM is 0.11

The 52-week high of Metropolis Healthcare Ltd share price is Rs. 2,067.95 while the 52-week low is Rs. 1,296.00

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 19, 2024 10:29 AM, the market cap of Metropolis Healthcare Ltd stood at Rs. 9,910.89.

Download App

Download Our App

Play Store App Store
market app